Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES

Transcription

1 Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete a Financial Relationships/Conflicts of Interest Disclosure Form prior to the Internet Live Course. A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount, and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced. IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et. al. conflicts of interest were identified, reviewed and resolved from all individuals involved in the development or able to influence and control the content of this CME activity. IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners. Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from future IASLC CME activity presentations. All commercial relationships and conflicts of interest identified were thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and/or an independent reviewer. COI was evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity. The following Financial Disclosures are from the speakers, moderators, reviewers, and planning committee members (et.al.) their spouse/life partner have disclosed regarding financial interest/arrangement or affiliation with any commercial interests that produce, market, re-sell, or distribute healthcare goods or services for patients that are relevant to this presentation(s) or that have provided commercial support for this continuing medical education activity:

2 Name DEPARTMENT Role Financial Disclosures Shakun Malik, William Travis, Elisabeth Brambilla, Ignacio Wistuba, Oncology Speaker Speakers or Advisory Board, Supported/Contracted Research/Grant Genentech/Roche, Bristol-Myers Squibb, Boehringer Ingelheim, Medscape, Astra Zeneca/Medimmune, Pfizer, Ariad, HTG Molecular, Roman Thomas, Kwon-Sik Park, David MacPherson, Trudy Oliver, Afshin Dowlati, Jane Johnson, Christin Kuo, Charles Rudin, Asuragen, Merck. Oncology Speaker New Oncology: (Advisory board / stock shareholder), AstraZeneca, Merck, Clovis, Puma, Daiichi-Sankyo, J&J, Sanofi-Aventis, Roche, Boehringer Ingelheim, MSD, Lilly, Bayer: Honoraria / AstraZeneca, EOS, Merck: Grant/Contracted Research Oncology Speaker Supported/Contracted Research/Grant: Roche Oncology Julien Sage, Mark Krasnow, Pierre Massion, Israel Canadas, Giuseppe Giaccone, Adi Gazdar, Speakers or Advisory Board: BMS - Advisor; G1 Therapeutics - Advisor; Harpoon Therapeutics - Advisor

3 Anton Berns, Caroline Dive, Patrick Nana- Sinkam, Leanne Li, John Poirier, Yves Pommier,, Camilla Christensen, Justin Gainor, Oncology Speaker Advisory Board: BMS, Genentech, Loxo, Theravance. Honoraria: Novartis, Merck, Ariad, Ignyta Fred Hirsh,, Oncology Speaker Speakers or Advisory Board: Genentech, Lilly, Ariad, HTG Molecular Diagnostics Scott Antonia, Anna Farago, Oncology Speaker Advisory board member: Abbvie/Stemcentrx, Merrimack Pharmaceuticals, Takeda. Consultant: Pharmamar SA. Speaker: Foundation Medicine. Paul Bunn, Oncology Speaker Speakers or Advisory Board: AstraZeneca,BMS, Merck,Merck- Serono,Daiichi,Genentech,Lilly,Merrimack,Novartis, Pfizer Lauren Byers, Christine Hann, Oncology Speaker Medivation, Inc. (Consulting); AstraZeneca Pharmaceuticals (Scientific Advisory Committee Member); AbbVie (Consulting); Lilly (Consulting, Speaking) Oncology Speaker Advisory Board: Abbvie Stemcentrx; Contracted Research: GlaxoSmithKline; Contracted Research: Merrimack Suresh Ramalingam, Oncology Speaker Advisory Board: Amgen, Astra Zeneca, Bristol Myers Squibb, Merck, Ariad, Genentech, Lilly, Novartis, Abbvie. Neal Ready, Oncology Speaker BMS advisory board and honoraria, Merck ad board, Novartis ad board, Abbvie ad board David Spigel, Nothing to Disclose David McFadden, John Minna, Beverly Teicher,

4 Keunchil Park, Oncology Speaker Speakers or Advisory Board : Astellas, AZ, BI, Clovis, Eli Lilly, Hanmi, MSD, ONO, Novartis, Roche John Heymach, Oncology Speaker Speakers or Advisory Board : Genetech, Astrazeneca, Bristoll Myers Squib and Lilly. Renata Ferrarotto, Pia Hirsch IASLC Planner Nothing to Disclose Carlos Ferreira IASLC Planner Nothing to Disclose Laurie Gaspar, University of Colorado Reviewer Nothing to Disclose CREDIT STATEMENT: IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. IASLC CME designates this Live Course activity for a maximum of 12.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. GOAL & PURPOSE: The program condenses the timeliest scientific and educational topics from multiple disciplines into a one or two-day event (typically 6-8 hours of educational sessions per day). Presented by regional teams recruited from multiple disciplines, the event brings the top abstracts as chosen by the experts on the WCLC Scientific Committee to professionals engaged in the diagnosis and treatment of lung cancer and related malignancies in a concise presentation. TARGET AUDIENCE: This CME live webinar was designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physician assistants. LEARNING OBJECTIVES: After attending this session, participants will: Identify effective global lung cancer prevention strategies. Improve their ability to participate in tobacco control and smoking cessation programs. Recognize the current approaches and strategies for early detection and screening of lung cancer. Demonstrate the best methods to implement multi-disciplinary tumor boards into community practices. Examine evidence-based therapeutic regimens for early stage and locally advanced NSCLC. Distinguish evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics. Define best practices regarding the application of targeted therapies for metastatic NSCLC in frontline and then subsequent settings following acquired resistance to the targeted therapy.

5 Describe current and emerging immunotherapy strategies in the context of clinical trials findings and patient selection in metastatic NSCLC. Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen. Review the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in nonacademic settings. DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient s conditions and possible contraindications on dangers in use, review of any applicable manufacturer s product information, and comparison with recommendations of other authorities. The content has been reviewed for conformity with ACCME Essentials, Policies, and Standards for Commercial Support. TO RECEIVE CME CREDIT: An evaluation link will be to the you provided. Upon completion of the electronic evaluation link the CME Certificate will be ready for you to print or save for your records. This information is used not only to evaluate the present activity, but also to plan for future programs.

6

7